Allergy Immunotherapy Market - By Type: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT). By Allergy Type: Seasonal Allergies, Perennial Allergies, Food Allergies, Others. By End-user: Hospitals, Clinics, Homecare. By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The global Allergy Immunotherapy Market was valued at 2.9 billion in 2023 and is projected to reach 6.7 billion by 2031, growing at a CAGR of 10.8%. Rising environmental allergies, increasing adoption of biologics, and patient preference for long-term solutions drive growth.
2024 Market Breakthroughs
Market Drivers
1. Epidemic-Level Allergy Rates
2. Regulatory Support
3. Patient Demand for Curative Solutions
Competitive Landscape
|
Company |
Market Share |
Flagship Product |
Strategic Edge |
|
ALK-Abelló |
32% |
Palforzia® (Peanut) |
FDA-first biologic approval |
|
Stallergenes Greer |
24% |
Oralair® (Grass Pollen) |
SLIT market leader |
|
DBV Technologies |
15% |
Viaskin™ Patch (Milk) |
Non-invasive innovation |
Emerging Disruptors:
Market Segmentation
Recent Developments (2024)
Global Allergy Immunotherapy Market Report
Need help?
Chat with our team in a minute.